Several studies comparing DPP-4 inhibitor regimens to basal-bolus insulin regimens have shown similar glycaemic benefits and these regimens have simplified the in-hospital management of T2D [11,12,13,14,15,16,17,18,19]. This evidence concerns the gene INS and type 2 diabetes mellitus.